Search results
Results from the WOW.Com Content Network
SIRT, when added to first line therapy for patients with metastases of colorectal cancer, was evaluated in the SIRFLOX, [12] FOXFIRE [13] and FOXFIRE Global [14] studies. For primary liver cancer (HCC), two large trials comparing SIRT with standard of care chemotherapy, Sorafenib, have been completed, namely the SARAH [15] and SIRveNIB [16] trials.
SIR-Spheres microspheres are used to treat patients with unresectable liver cancer. These are mostly patients with hepatocellular carcinoma (HCC), metastatic colorectal cancer (mCRC), or metastatic neuroendocrine tumours (mNET). [1] Therapy goals are local disease control, downstaging to resection, bridging to transplantation, and extended ...
For premium support please call: 800-290-4726 more ways to reach us
Most tumors within the liver are supplied by the proper hepatic artery, so arterial embolization preferentially interrupts the tumor's blood supply and stalls growth until neovascularization. Secondly, focused administration of chemotherapy allows for delivery of a higher dose to the tissue while simultaneously reducing systemic exposure, which ...
The Living to 100 Life Expectancy Calculator gave me a surprisingly precise prediction: "You're going to live for 27 more years!" But it suggested I might add three months to my life if I cut down ...
The Model for End-Stage Liver Disease, or MELD, is a scoring system for assessing the severity of chronic liver disease.It was initially developed to predict mortality within three months of surgery in patients who had undergone a transjugular intrahepatic portosystemic shunt (TIPS) procedure, [1] and was subsequently found to be useful in determining prognosis and prioritizing for receipt of ...
For premium support please call: 800-290-4726 more ways to reach us
Small cell lung cancer has a five-year survival rate of 4% according to Cancer Centers of America's Website. [5] The American Cancer Society reports 5-year relative survival rates of over 70% for women with stage 0-III breast cancer with a 5-year relative survival rate close to 100% for women with stage 0 or stage I breast cancer.